JI-101

• Description:

  JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Ephrin Receptor; PDGFR; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/JI-101.html

• Purity:

  99.78

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(NC1=CC(Br)=CC=C1OC)NC2=CC=CC3=C2C=CN3CC4=CC(N)=NC=C4

• Molecular Formula:

  C22H20BrN5O2

• Molecular Weight:

  466.33

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Gurav SD, et al. Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats. Arzneimittelforschung. 2012 Jan;62 (1) :27-34.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  PDGFRβ; VEGFR2/KDR/Flk-1

• CAS Number:

  [900573-88-8]